VACC Stock Overview
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.56|
|52 Week High||US$17.99|
|52 Week Low||US$2.97|
|1 Month Change||-22.55%|
|3 Month Change||-50.12%|
|1 Year Change||-68.74%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-67.68%|
Recent News & Updates
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
Vaccitech plc ( NASDAQ:VACC ) shareholders will have a reason to smile today, with the analysts making substantial...
|VACC||US Biotechs||US Market|
Return vs Industry: VACC underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: VACC underperformed the US Market which returned -12.9% over the past year.
|VACC Average Weekly Movement||18.2%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: VACC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: VACC's weekly volatility has increased from 11% to 18% over the past year.
About the Company
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company’s therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection.
Vaccitech Fundamentals Summary
|VACC fundamental statistics|
Is VACC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VACC income statement (TTM)|
|Cost of Revenue||US$26.46m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.89|
|Net Profit Margin||-218.97%|
How did VACC perform over the long term?See historical performance and comparison
Is Vaccitech undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VACC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VACC's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: VACC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: VACC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VACC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VACC is good value based on its PB Ratio (0.7x) compared to the US Biotechs industry average (1.5x).
How is Vaccitech forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VACC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VACC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VACC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VACC's revenue is expected to decline over the next 3 years (-45.3% per year).
High Growth Revenue: VACC's revenue is forecast to decline over the next 3 years (-45.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VACC is forecast to be unprofitable in 3 years.
How has Vaccitech performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: VACC is currently unprofitable.
Growing Profit Margin: VACC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if VACC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare VACC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VACC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: VACC has a negative Return on Equity (-13.1%), as it is currently unprofitable.
How is Vaccitech's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VACC's short term assets ($230.8M) exceed its short term liabilities ($16.5M).
Long Term Liabilities: VACC's short term assets ($230.8M) exceed its long term liabilities ($16.5M).
Debt to Equity History and Analysis
Debt Level: VACC is debt free.
Reducing Debt: VACC had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VACC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VACC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.3% each year
What is Vaccitech current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VACC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VACC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VACC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VACC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VACC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bill Enright (58 yo)
Mr. William J. Enright, also known as Bill, MBA, serves as Chief Executive Officer & Director of Vaccitech plc since August 2019. He brings a breadth of experiences in a variety of positions within the lif...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD2.74M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
Experienced Management: VACC's management team is considered experienced (2.8 years average tenure).
Experienced Board: VACC's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.2%.
Vaccitech plc's employee growth, exchange listings and data sources
- Name: Vaccitech plc
- Ticker: VACC
- Exchange: NasdaqGM
- Founded: 2016
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$169.537m
- Shares outstanding: 37.20m
- Website: https://www.vaccitech.co.uk
Number of Employees
- Vaccitech plc
- The SchrOedinger Building
- Heatley Road
- OX4 4GE
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.